Analysts expect ArQule, Inc. (NASDAQ:ARQL) to announce earnings per share (EPS) of ($0.11) for the current quarter, Zacks reports. Zero analysts have issued estimates for ArQule’s earnings. ArQule reported earnings of ($0.07) per share during the same quarter last year, which suggests a negative year over year growth rate of 57.1%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, August 2nd.

On average, analysts expect that ArQule will report full-year earnings of ($0.45) per share for the current financial year. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.40) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for ArQule.

ArQule (NASDAQ:ARQL) last posted its earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.11). ArQule had a negative net margin of 296.69% and a negative return on equity of 55.62%. During the same quarter last year, the business posted ($0.08) EPS.

Separately, Zacks Investment Research cut shares of ArQule from a “hold” rating to a “sell” rating in a report on Thursday, May 4th.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC boosted its position in shares of ArQule by 3.3% in the third quarter. Nantahala Capital Management LLC now owns 9,263,041 shares of the biotechnology company’s stock valued at $16,303,000 after buying an additional 298,996 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of ArQule by 1.5% in the first quarter. Vanguard Group Inc. now owns 3,021,618 shares of the biotechnology company’s stock valued at $3,203,000 after buying an additional 45,924 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of ArQule by 1.4% in the fourth quarter. Renaissance Technologies LLC now owns 2,017,600 shares of the biotechnology company’s stock valued at $2,542,000 after buying an additional 26,900 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of ArQule by 0.4% in the first quarter. Geode Capital Management LLC now owns 323,680 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 1,152 shares in the last quarter. Hedge funds and other institutional investors own 58.99% of the company’s stock.

ArQule (NASDAQ ARQL) opened at 1.305 on Monday. The firm’s market cap is $92.85 million. The stock has a 50 day moving average of $1.07 and a 200-day moving average of $1.25. ArQule has a 12 month low of $0.92 and a 12 month high of $2.17.

COPYRIGHT VIOLATION WARNING: “Analysts Expect ArQule, Inc. (ARQL) to Announce -$0.11 EPS” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/06/05/analysts-expect-arqule-inc-arql-to-announce-0-11-eps.html.

About ArQule

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.